Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 80 for “"Base Editing"”.
-
Improved Base Editing Technologies With Novel Editors and Assays
… recent development of second-generation CRISPR editing tools has opened even more doors into how the human genome can be manipulated. Past methods to introduce a single-base substitution into genomes involved creating a double-strand break and taking advantage of the cellular repair pathway …
-
Advancing RNA base editing treatments for inherited retinal disease
… photoreceptors and Müller glia cells. RNA base editing utilises the adenine deaminase acting on RNA (ADAR) enzyme to target G-to-A transition mutations in the transcriptome, eschewing the risk of inducing permanent local or genome-wide off-target effects. This thesis aims to compare and …
-
Translational control via viral protease activated stop codon base editing
… the development and characterization of RNA-editing enzymes based on adenosine deaminase acting on RNA (ADAR) that have been engineered to activate in response to viral protease is discussed. Specifically, methods for targeting ADAR editing to specific mRNA transcripts and strategies in which …
-
DEVELOPING BASE EDITING AND PRIME EDITING THERAPIES FOR THE TREATMENT OF PHENYLKETONURIA
… (p.R408W) and c.842C>T (p.P281L). Genome editing has the unique ability to directly correct these pathogenic variants and offers the potential for durable and curative therapies to address the unmet medical needs of PKU patients. Through this work, we have established a pipeline to rapidly …
-
Development of reporter mouse models to evaluate and optimize crispr/cas9 base editing therapeutics
… limited therapeutic benefit to patients. Genome editing provides a new therapeutic strategy to treat genetic diseases. In the last few years, the Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system has emerged as a promising gene editing …
-
CRISPR/Cas9-mediated base editing in limb-girdle muscular dystrophy type 2A-causing mutations
… of curative therapies, precise ex vivo genome editing of patient-derived cells represents a promising therapeutic strategy. In this study, an adenine base editing (ABE) framework was established to correct clinically relevant CAPN3 point mutations in patient-derived primary human satellite …
-
A Strain-Specific Mechanism Drives Cytosine to Guanine Conversion During Cytidine Base Editing in Streptomyces
… repeats (CRISPR)-Cas system has facilitated gene editing of different organisms. Specifically, programmable base editing enables stable conversion of a single nucleotide to another nucleotide without causing DNA double-strand breaks. Cas9-derived base editors (BEs), including adenine BEs (ABEs) …
-
Base editing enables single-step, highly multiplex genome editing in human IPSCs with negligible genotoxicity
… of engineered immune cells; however, multiplex editing using Cas9 nucleases to enhance effector function and overcome the immunosuppressive tumor microenvironment (TME) poses significant risks for genotoxicity and chromosomal translocations. To mitigate risks associated with double-stranded …
-
Attempts to rescue canonical frataxin expression by base editing: Kozak sequence and alternative splicing reprogramming
… normal frataxin protein levels and genome editing approaches, have demonstrated encouraging results in cellular and animal models, providing a proof-of-principle of the efficacy of frataxin restoration. These approaches are at different stages of pre-clinical or early clinical development. …
-
CRISPR/Cas-Mediated Base Editing to Correct Recurrent Point Mutations in Tumors of the Central Nervous System
… for further study. CRISPR/Cas-mediated adenine base editing, which enables precise and targeted conversion of A•T to G•C base pairs, was applied to precisely convert the mutated locus to a wildtype sequence.
-
REPURPOSING CLINICALLY DERIVED LIPID NANOPARTICLE FORMULATIONS FOR EFFICIENT AND SAFE CRISPR BASE EDITING IN THE LIVER AND RETINA
… delivery of large gene editors such as adenine base editors remains challenging and appears to require tissue-specific formulation optimization. This thesis presents a structure–property–function approach to repurpose and rationally optimize clinically derived LNP formulations for CRISPR base …
-
Therapeutic genome editing for the treatment of genetic diseases : testing the safety and effectiveness of CRISPR/Cas9 therapeutic base editing
… project was to optimize a novel CRISPR/Cas9 ‘base editing’ approach to treat genetic diseases by specifically repairing the disease-causing mutation in situ in the patients’ DNA. This technology uses a fusion of a partially deactivated Cas9 (nCas9) protein coupled with a nucleotide modifying …
-
Developing base-editing for the improvement of agronomic traits in field peas (Pisum sativum) using glyphosate resistance as a target
… has come an increased push towards more plant-based diets as plant agriculture has lower greenhouse gas emissions (GHGs) and land use requirements than animal agriculture. Field peas (Pisum sativum), an important Canadian crop, lend themselves well to this shift due to their high protein …
-
The Design and In-Vitro Validation of Therapeutic CRISPR Base Editing and AAV-9 Gene Therapy for the Treatment of Classic Galactosemia
… gene replacement therapy, and a CRISPR cytosine base editor therapy. We observed that our AAV-9 expression plasmid for human GALT enzyme successfully restored enzyme levels in the substitution in Q188R homozygous patient fibroblast cells as shown through western blotting. However, biochemical …
-
Base editing of Galactose-1-Phosphate Uridylyl Transferase as a novel gene therapy approach to treat Q188R mutation in a cellular model of Classic Galactosemia
… galactitol. The Q188R mutation is caused by a base change from adenine to guanine in base pair 563. This mutation causes an amino acid change in position 188 from glutamine (Gln) to arginine (Arg) and is responsible for 60-70% of CG cases in homozygous state. Consequently, affected infants …
-
Characterization of $\textit{in Vivo}$ Base – And Prime Editing for the Treatment of Liver and Brain Diseases
The application of genome editing in medicine to treat genetic diseases has gained momentum with the development of advanced CRISPR tools. Base and prime editors offer the ability to introduce precise single-nucleotide changes without causing double-strand breaks, thereby reducing the risk of …
-
Correction of a pathogenic lipoprotein lipase deficiency mutation p207l using Crispr/Cas-mediated adenine base editors
… Previously, our lab developed an AAV-based gene therapy to treat LPL deficiency by delivering the LPL gene into patients demonstrating proof of concept for viral-based gene therapy. This treatment became the first gene-augmentation therapy to receive regulatory approval (Glybera®). One …
-
Development of CRISPR gene therapy for retinal degenerations
… (Cas) nuclease system has enabled facile gene editing of human cells. Herein, I explore CRISPR-Cas mediated gene editing of both DNA and RNA, to develop therapeutic strategies to alter or correct genes implicated in IRD pathogenesis.</p> <p>This thesis firstly investigated aspects of …
-
MATERIAL AND BIOLOGICAL ENGINEERING OF LIPID NANOPARTICLE AND CRISPR GENE EDITOR SYSTEM FOR IN VIVO PRECISION MEDICINE
… in principle, correctable using precision gene editing technologies such as base editing and prime editing. Majority of these coagulation factors are synthesized in hepatocytes, thereby making the liver an ideal target for therapeutic intervention. Lipid nanoparticles (LNPs) have emerged as a …
-
Molecular techniques for therapeutic and diagnostic applications in Mucopolysaccharidosis IIIB and Gaucher disease
… of GD, are neurodegenerative, cell and gene-based therapeutic strategies are of significant interest. Therapeutics that offer some symptom mitigation in other LDs, such as enzyme replacement or substrate reduction therapies, do not offer appreciable disease mitigation in MPS IIIB or …
Page 1 of 4